Results 121 to 130 of about 64,954 (254)

Proteolysis at the extracellular matrix interface: Molecular architects and regulators in health and disease

The FEBS Journal, EarlyView.
The extracellular matrix (ECM) is a dynamic scaffold that orchestrates tissue architecture and cellular communication. A critical but underexplored interplay between proteases and cluster of differentiation molecules (CD) governs ECM turnover and directs cell fate.
David Jurnečka, Matija Hrovatin, Bor Bokalj, Boris Turk   +3 more
wiley   +1 more source

Humanized anti-CD33 CAR-T cells and antibody-drug conjugates for targeted therapy in acute myeloid leukemia. [PDF]

Front Med (Lausanne)
Chen L, Duan H, Huang C, Xu Y, Wang Z, Huang H.   +5 more
europepmc   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

scFv-based biologics in diabetes: from therapeutic potential to clinical prospects. [PDF]

Front Immunol
Ge S, Wang L, Huang Y, Guo H, Wei F, Li P, Li S, Liu Q, Xu J, Xiao Y, Piress Dias AC, Ji L.   +11 more
europepmc   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source

Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study

Haemophilia, EarlyView.
ABSTRACT Background Despite effective bleed prevention with Emicizumab, pain remains a relevant clinical burden in adults with severe haemophilia A (sHA). A multidimensional assessment is needed to better characterize contemporary haemophilia‐related pain.
Ilenia Lorenza Calcaterra, Sofia Donnarumma, Guido D'Errico, Carmine De Luca, Chiara Caputo, Paola Ciciola, Ernesto Cimino, Matteo Di Minno   +7 more
wiley   +1 more source

Applications of humanized mice in <i>Mycobacterium tuberculosis</i> infections (Review). [PDF]

Mol Med Rep
Han B, Liu F, Long J, Wang J, Cui Y, Yang H.   +5 more
europepmc   +1 more source

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3

Haemophilia, EarlyView.
ABSTRACT Introduction Tissue factor pathway inhibitor (TFPI), a key regulator of tissue factor‐initiated coagulation through FXa‐dependent inhibition of the tissue factor‐FVIIa complex, has emerged as a promising target for restoring thrombin generation.
Mankai Ju, Feng Xue, Wei Sun, Fang Li, Ting Xu, Renchi Yang   +5 more
wiley   +1 more source

FDA Approval of Donanemab-azbt: A New Dawn in Alzheimer's Disease Treatment. [PDF]

Health Sci Rep
Riaz R, Fatima M, Ramzan S, Rathi D, Fatima F, Farooq M, Shaukat A, Khaliq N, Akilimali A.   +8 more
europepmc   +1 more source

Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer

Histopathology, EarlyView.
c‐Met protein overexpression can be assessed before or after treatment in patients with non‐squamous NSCLC since most patients maintain a consistent c‐Met status. However, as targeted therapies may elevate c‐Met overexpression, retesting may be necessary for subsets of patients.
Alexis B Cortot, Romain Dubois, Valérie Grégoire, Jean‐Baptiste Gibier, Julien Labreuche, Virginie Deprez, Déborah Dubrulle, Thomas Chretien, Eric Wasielewski, Hélène Behal, Dai Feng, Amber Lind, Peter Ansell, Raphaële Thiébaut‐Millot, Carlos Hader   +14 more
wiley   +1 more source